(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2011 (07.04.2011)

PCT

(10) International Publication Number
WO 2011/041785 A1

(51) International Patent Classification:
G01N 33/50 (2006.01)

(21) International Application Number:
PCT/US2010/051341

(22) International Filing Date:
4 October 2010 (04.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/248,270	2 October 2009 (02.10.2009)	US
61/255,805	28 October 2009 (28.10.2009)	US
61/323,771	13 April 2010 (13.04.2010)	US
61/380,685	7 September 2010 (07.09.2010)	US

(71) Applicant *(for all designated States except US)*: **CYLENE PHARMACEUTICALS, INC.** [US/US]; 5820 Nancy Ridge Drive, Suite 200, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DRYGIN, Denis** [RU/US]; 14125 Via Alisal, San Diego, California 92128 (US). **O'BRIEN, Sean** [GB/US]; 2958 Emerald Place, Carlsbad, California 90029 (US). **ANDERES, Kenna** [US/US]; 5522 Mill Creek Road, San Diego, California 92130 (US). **VONHOFF, Daniel, D.** [—/US]; San Diego, California (US). **LIM, John, K., C.** [—/US]; San Diego, California (US). **PADGETT, Claire, S.** [—/US]; San Diego, California (US). **BLIESATH, Joshua, R.** [US/US]; 1306 Scenic Drive, Escondido, California 92029 (US). **HO, Caroline, B.** [CA/US]; 15540 Sumac Terrace, Valley Center, California 92082 (US). **RICE, William G.** [US/US]; 13601 Nogales Drive, San Diego, California 92014 (US).


(74) Agents: **WU, Nan** et al.; Cooley LLP, 777 6th Street, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS

FIGURE 1



(57) Abstract: Disclosed are biomarkers for determining the sensitivity of protein kinase CK2-mediated diseases, such as proliferative and/or inflammatory disorders, to treatment with CK2 inhibitors. These biomarkers can be used to predict or select subjects likely to be responsive to treatment with a CK2 inhibitor, and to treat or monitor subjects undergoing treatment with a CK2 inhibitor.

WO 2011/041785 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*